Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease
2024

Immunotherapy for Chronic Active Epstein-Barr Virus Disease

Sample size: 16 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yan Sijia, Ming Xi, Zhu Xiaojian, Xiao Yi

Primary Institution: Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Hypothesis

Can immunotherapy improve treatment outcomes for patients with chronic active Epstein-Barr virus disease?

Conclusion

Immunotherapy shows promise in treating chronic active Epstein-Barr virus disease, with various approaches demonstrating safety and efficacy.

Supporting Evidence

  • Immunotherapy drugs, including PD-1 inhibitors, have shown safety and efficacy in treating chronic active Epstein-Barr virus disease.
  • Patients treated with PD-1 inhibitors had a median progression-free survival of 11.1 months.
  • Combination therapy with PD-1 inhibitors and lenalidomide resulted in a 54.2% overall response rate.

Takeaway

This study looks at how new treatments using the immune system can help people with a serious virus infection called chronic active Epstein-Barr virus disease.

Methodology

The study reviews various immunotherapy approaches and their effectiveness in treating chronic active Epstein-Barr virus disease.

Limitations

The sample sizes in some studies were small, and further research is needed to confirm findings.

Participant Demographics

The median age of participants was 33 years, with a range from 11 to 67 years.

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1451977

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication